A Phase 1 interventional study of HL237 and Placebo Oral Tablet in Rheumatoid Arthritis, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-17.
Sponsored by Hanlim Pharm. Co., Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of — 9 open to participants now, 15 under way, 2 of them phase 3. Arthritis, Rheumatoid · Korea, Republic of.
Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, this one is the 135th largest by enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2017, is one of 20 in phase 1, and was the 149th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of are open now. Recruiting first, the newest first:
AbbVie · Sites in Korea, Republic of, United States, Canada and 9 more countries
Ages 18+
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 18+
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Eisai Korea Inc. · Sites in Korea, Republic of
Ages 18+
Gangnam Severance Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 32 · Phase 3 74 · Phase 4 20
First in 2002; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 155 interventional studies, 425 across the 33 observational. Of the 156 that completed or were terminated, 93 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 188 have an industry lead sponsor. The 10 most frequent:
Hanlim Pharm. Co., Ltd. is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Hanlim Pharm. Co., Ltd. has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
4 of the studies in Arthritis, Rheumatoid with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT07675226Oscotec Inc.Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions | 2026-12-31 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06246123Eisai Korea Inc.A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic structure of biguanide in metformin, an existing diabetes drug.
The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3 inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and activating Treg cells.
Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune diseases such as rheumatoid arthritis.
This is the first clinical trial to be conducted for the development of HL237 and this clinical trial is for determining the maximum oral dose of HL237 and assessing safety, tolerability, and pharmacokinetic characteristics for each dose group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
take oral tablet once
Drug: HL237 · Drug: Placebo Oral Tablet
Experimental
placebo with same properties except for active ingredient
Maximum Plasma Concentration [Cmax]
maximum serum concentration after the drug has been administrated
Time frame: 3days after administration
Area Under the Curve [AUC]
Time frame: 3days after administration
half life [t1/2]
Time frame: 3days after administration
Number of participants with treatment-related adverse events
Time frame: 14days after administration
Ran from Jun 2017 to primary completion in Mar 2018, 8 months.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 8 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HL237